BridgeBio Pharma Adds $125M

Palo Alto-based BridgeBio Pharma, a biopharmaceuticals developer focused on genetic diseases, said on Wednesday that it has raised $135M in a funding round

The story you have requested is only available to paid members of the web site. Stories newer than 15 days are restricted to paid members only. Please login in order to access this members-only content, or become a member.